Q4 Earnings Estimate for Annovis Bio Issued By HC Wainwright

Annovis Bio, Inc. (NYSE:ANVS) – Stock analysts at HC Wainwright reduced their Q4 2024 earnings per share (EPS) estimates for shares of Annovis Bio in a report issued on Monday, November 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.38) per share for the quarter, down from their prior forecast of ($0.30). HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Annovis Bio’s current full-year earnings is ($1.99) per share. HC Wainwright also issued estimates for Annovis Bio’s Q1 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.76) EPS and FY2025 earnings at ($2.32) EPS.

Several other analysts have also recently weighed in on ANVS. Maxim Group raised shares of Annovis Bio from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Friday, October 25th. EF Hutton Acquisition Co. I raised Annovis Bio to a “strong-buy” rating in a research note on Tuesday, August 13th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $32.17.

Annovis Bio Stock Performance

Shares of NYSE ANVS opened at $6.94 on Thursday. The firm has a 50 day moving average price of $8.47 and a two-hundred day moving average price of $8.27. The stock has a market cap of $95.77 million, a P/E ratio of -1.66 and a beta of 1.70. Annovis Bio has a 52-week low of $4.53 and a 52-week high of $22.49.

Annovis Bio (NYSE:ANVS) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.33).

Institutional Investors Weigh In On Annovis Bio

Several large investors have recently added to or reduced their stakes in ANVS. Greenwich Wealth Management LLC boosted its stake in Annovis Bio by 19.9% during the second quarter. Greenwich Wealth Management LLC now owns 15,075 shares of the company’s stock worth $87,000 after acquiring an additional 2,500 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Annovis Bio during the second quarter valued at about $115,000. Cetera Advisors LLC bought a new position in shares of Annovis Bio during the 1st quarter worth about $122,000. Quest Partners LLC acquired a new stake in shares of Annovis Bio in the 3rd quarter valued at about $371,000. Finally, Vanguard Group Inc. increased its position in Annovis Bio by 6.1% in the 1st quarter. Vanguard Group Inc. now owns 357,942 shares of the company’s stock valued at $4,260,000 after buying an additional 20,588 shares in the last quarter. Institutional investors and hedge funds own 15.83% of the company’s stock.

About Annovis Bio

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.